> top > docs > PubMed:26255059 > annotations

PubMed:26255059 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T3 79-103 D002285 denotes ductal carcinoma in situ
T4 79-103 D002285 denotes ductal carcinoma in situ
T10 105-109 CVCL_5552 denotes DCIS
T9 105-109 D002285 denotes DCIS
T11 105-109 D002285 denotes DCIS
T12 143-152 D002277 denotes carcinoma
T13 143-152 D002277 denotes carcinoma
T14 174-181 P02855 denotes type: a
T15 182-186 PR:000023208 denotes meta
T16 182-186 PR:P07623 denotes meta
T19 204-221 D002278 denotes carcinoma in situ
T20 204-221 D002278 denotes carcinoma in situ
T22 223-227 CVCL_5552 denotes DCIS
T21 223-227 D002285 denotes DCIS
T23 223-227 D002285 denotes DCIS
T26 234-237 SO:0002045 denotes pre
T25 234-237 PR:Q8LLD0 denotes pre
T27 234-237 UBERON:0001782 denotes pre
T24 234-237 GO:0003904 denotes pre
T28 247-257 D009369 denotes malignancy
T29 247-257 D009369 denotes malignancy
T30 382-392 D012008 denotes recurrence
T31 382-392 D012008 denotes recurrence
T32 420-429 D002277 denotes carcinoma
T33 420-429 D002277 denotes carcinoma
T34 491-501 D015415 denotes biomarkers
T35 491-501 D015415 denotes biomarkers
T36 537-547 D012008 denotes recurrence
T37 537-547 D012008 denotes recurrence
T38 574-581 D004194 denotes disease
T39 574-581 D004194 denotes disease
T40 632-636 PR:000023208 denotes meta
T41 632-636 PR:P07623 denotes meta
T42 730-734 PR:Q8FYW3 denotes pure
T43 730-734 PR:Q54QE4 denotes pure
T44 730-734 PR:P52558 denotes pure
T45 730-734 PR:P0AG18 denotes pure
T47 730-734 PR:000023640 denotes pure
T46 730-734 GO:0034023 denotes pure
T49 736-740 CVCL_5552 denotes DCIS
T48 736-740 D002285 denotes DCIS
T50 736-740 D002285 denotes DCIS
T52 752-756 CVCL_5552 denotes DCIS
T51 752-756 D002285 denotes DCIS
T53 752-756 D002285 denotes DCIS
T54 782-791 D002277 denotes carcinoma
T55 782-791 D002277 denotes carcinoma
T56 847-856 D002277 denotes carcinoma
T57 847-856 D002277 denotes carcinoma
T58 899-926 D002285 denotes atypical ductal hyperplasia
T59 899-926 D002285 denotes atypical ductal hyperplasia
T62 928-931 P0A388 denotes ADH
T63 928-931 PR:P06525 denotes ADH
T64 928-931 Q8NXU1 denotes ADH
T65 928-931 Q6GBM4 denotes ADH
T66 928-931 Q47945 denotes ADH
T67 928-931 P0A389 denotes ADH
T68 928-931 Q5HRD6 denotes ADH
T69 928-931 P28036 denotes ADH
T70 928-931 P42327 denotes ADH
T71 928-931 PR:P00332 denotes ADH
T74 928-931 P81786 denotes ADH
T75 928-931 P18278 denotes ADH
T76 928-931 Q44002 denotes ADH
T77 928-931 Q7A742 denotes ADH
T78 928-931 O05542 denotes ADH
T79 928-931 Q2YSX0 denotes ADH
T80 928-931 Q6GJ63 denotes ADH
T81 928-931 PR:P00334 denotes ADH
T83 928-931 Q24857 denotes ADH
T84 928-931 Q8CQ56 denotes ADH
T85 928-931 Q2FJ31 denotes ADH
T86 928-931 Q2G0G1 denotes ADH
T87 928-931 PR:Q2G0G1 denotes ADH
T89 928-931 Q5HI63 denotes ADH
T90 928-931 Q99W07 denotes ADH
T91 928-931 Q04983 denotes ADH
T72 928-931 CHEBI:34543 denotes ADH
T88 928-931 CHEBI:9937 denotes ADH
T73 928-931 GO:0047636 denotes ADH
T82 928-931 GO:0004022 denotes ADH
T92 962-968 SO:0001026 denotes genome
T93 988-996 SO:0000341 denotes cytoband
T94 1014-1020 SO:0001026 denotes genome
T95 1103-1109 CVCL_E017 denotes Fisher
T96 1103-1109 76720 denotes Fisher
T97 1175-1179 SO:0001742 denotes gain
T98 1206-1214 SO:0000341 denotes cytoband
T100 1268-1272 CVCL_5552 denotes DCIS
T99 1268-1272 D002285 denotes DCIS
T101 1268-1272 D002285 denotes DCIS
T102 1332-1336 PR:Q8FYW3 denotes pure
T103 1332-1336 PR:Q54QE4 denotes pure
T104 1332-1336 PR:P52558 denotes pure
T105 1332-1336 PR:P0AG18 denotes pure
T107 1332-1336 PR:000023640 denotes pure
T106 1332-1336 GO:0034023 denotes pure
T109 1337-1341 CVCL_5552 denotes DCIS
T108 1337-1341 D002285 denotes DCIS
T110 1337-1341 D002285 denotes DCIS
T111 1411-1418 D004194 denotes disease
T112 1411-1418 D004194 denotes disease
T113 1462-1470 SO:0000341 denotes cytoband
T114 1538-1546 SO:0000341 denotes cytoband
T115 1590-1595 UBERON:0002542 denotes scale
T116 1597-1600 CVCL_Z893 denotes ECS
T117 1683-1686 CVCL_Z893 denotes ECS
T118 1776-1785 D009369 denotes neoplasia
T119 1776-1785 D009369 denotes neoplasia
T120 1795-1798 P0A388 denotes ADH
T121 1795-1798 PR:P06525 denotes ADH
T122 1795-1798 Q8NXU1 denotes ADH
T123 1795-1798 Q6GBM4 denotes ADH
T124 1795-1798 Q47945 denotes ADH
T125 1795-1798 P0A389 denotes ADH
T126 1795-1798 Q5HRD6 denotes ADH
T127 1795-1798 P28036 denotes ADH
T128 1795-1798 P42327 denotes ADH
T129 1795-1798 PR:P00332 denotes ADH
T132 1795-1798 P81786 denotes ADH
T133 1795-1798 P18278 denotes ADH
T134 1795-1798 Q44002 denotes ADH
T135 1795-1798 Q7A742 denotes ADH
T136 1795-1798 O05542 denotes ADH
T137 1795-1798 Q2YSX0 denotes ADH
T138 1795-1798 Q6GJ63 denotes ADH
T139 1795-1798 PR:P00334 denotes ADH
T141 1795-1798 Q24857 denotes ADH
T142 1795-1798 Q8CQ56 denotes ADH
T143 1795-1798 Q2FJ31 denotes ADH
T144 1795-1798 Q2G0G1 denotes ADH
T145 1795-1798 PR:Q2G0G1 denotes ADH
T147 1795-1798 Q5HI63 denotes ADH
T148 1795-1798 Q99W07 denotes ADH
T149 1795-1798 Q04983 denotes ADH
T130 1795-1798 CHEBI:34543 denotes ADH
T146 1795-1798 CHEBI:9937 denotes ADH
T131 1795-1798 GO:0047636 denotes ADH
T140 1795-1798 GO:0004022 denotes ADH
T150 1803-1807 PR:Q8FYW3 denotes pure
T151 1803-1807 PR:Q54QE4 denotes pure
T152 1803-1807 PR:P52558 denotes pure
T153 1803-1807 PR:P0AG18 denotes pure
T155 1803-1807 PR:000023640 denotes pure
T154 1803-1807 GO:0034023 denotes pure
T157 1808-1812 CVCL_5552 denotes DCIS
T156 1808-1812 D002285 denotes DCIS
T158 1808-1812 D002285 denotes DCIS
T159 1938-1945 D004194 denotes disease
T160 1938-1945 D004194 denotes disease

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-196 DRI_Background denotes Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis.
T2 197-326 DRI_Background denotes Ductal carcinoma in situ (DCIS) is a pre-invasive malignancy detected with an increasing frequency through screening mammography.
T3 327-481 DRI_Background denotes One of the primary aims of therapy is to prevent local recurrence, as in situ or as invasive carcinoma, the latter arising in half of the recurrent cases.
T4 482-603 DRI_Background denotes Reliable biomarkers predictive of its association with recurrence, particularly as invasive disease, are however lacking.
T5 604-933 DRI_Approach denotes In this study, we perform a meta-analysis of 26 studies which report somatic copy number aberrations (SCNAs) in 288 cases of 'pure' DCIS and 328 of DCIS associated with invasive carcinoma, along with additional unmatched cases of 145 invasive carcinoma of ductal/no special type (IDC) and 50 of atypical ductal hyperplasia (ADH).
T6 934-1102 DRI_Approach denotes SCNA frequencies across the genome were calculated at cytoband resolution (UCSC genome build 19) to maximally utilize the available information in published literature.
T7 1103-1246 DRI_Approach denotes Fisher's exact test was used to identify significant differences in the gain-loss distribution in each cytoband in different group comparisons.
T8 1247-1370 DRI_Outcome denotes We found synchronous DCIS to be at a more advanced stage of genetic aberrations than pure DCIS and was very similar to IDC.
T9 1371-1432 DRI_Approach denotes Differences in gains and losses in each disease process (i.e.
T10 1433-1676 DRI_Background denotes invasive or in situ) at each cytoband were used to infer evidence of selection and conservation for each cytoband and to define an evolutionary conservation scale (ECS) as a tool to identify and distinguish driver SCNA from the passenger SCNA.
T11 1677-1791 DRI_Outcome denotes Using ECS, we have identified aberrations that show evidence of selection from the early stages of neoplasia (i.e.
T12 1792-1946 DRI_Challenge denotes in ADH and pure DCIS) and persist in IDC; we postulate these to be driver aberrations and that their presence may predict progression to invasive disease.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 197-326 DRI_Background denotes Ductal carcinoma in situ (DCIS) is a pre-invasive malignancy detected with an increasing frequency through screening mammography.
T2 327-481 DRI_Background denotes One of the primary aims of therapy is to prevent local recurrence, as in situ or as invasive carcinoma, the latter arising in half of the recurrent cases.
T3 482-603 DRI_Background denotes Reliable biomarkers predictive of its association with recurrence, particularly as invasive disease, are however lacking.
T4 604-933 DRI_Approach denotes In this study, we perform a meta-analysis of 26 studies which report somatic copy number aberrations (SCNAs) in 288 cases of 'pure' DCIS and 328 of DCIS associated with invasive carcinoma, along with additional unmatched cases of 145 invasive carcinoma of ductal/no special type (IDC) and 50 of atypical ductal hyperplasia (ADH).
T5 934-1102 DRI_Approach denotes SCNA frequencies across the genome were calculated at cytoband resolution (UCSC genome build 19) to maximally utilize the available information in published literature.
T6 1103-1246 DRI_Approach denotes Fisher's exact test was used to identify significant differences in the gain-loss distribution in each cytoband in different group comparisons.
T7 1247-1370 DRI_Outcome denotes We found synchronous DCIS to be at a more advanced stage of genetic aberrations than pure DCIS and was very similar to IDC.
T8 1371-1432 DRI_Approach denotes Differences in gains and losses in each disease process (i.e.
T9 1433-1676 DRI_Background denotes invasive or in situ) at each cytoband were used to infer evidence of selection and conservation for each cytoband and to define an evolutionary conservation scale (ECS) as a tool to identify and distinguish driver SCNA from the passenger SCNA.
T10 1677-1791 DRI_Outcome denotes Using ECS, we have identified aberrations that show evidence of selection from the early stages of neoplasia (i.e.
T11 1792-1946 DRI_Challenge denotes in ADH and pure DCIS) and persist in IDC; we postulate these to be driver aberrations and that their presence may predict progression to invasive disease.